Merck MRK has a strong foothold in the oncology market, primarily supported by its biggest revenue driver, Keytruda. The blockbuster PD-1 inhibitor accounts for around 55% of the company’s ...

Merck MRK is focusing on driving long-term growth through the newer products and a promising set of pipelines as its ...

Merck said on Monday it would split its business into two, creating ⁠a division for its cancer franchise while grouping its ​non-oncology treatments separately.

Merck has called it quits on another attempt to enhance its powerful PD-1 inhibitor Keytruda in non-small cell lung cancer (NSCLC). Adding AstraZeneca-partnered Lynparza to Keytruda as a maintenance ...

For all its success across a wide range of cancer types, Merck’s PD-1 superstar Keytruda has never been able to crack the code for one of the toughest-to-treat indications in oncology—ovarian cancer.

Late-breaking results from the Phase 3 KEYNOTE-B15 trial were selected for the official Press Program and will be presented at the 2026 American Society of Clinical Oncology (ASCO) Genitourinary (GU) ...